Windtree Therapeutics, Inc.
WINTDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How WINT's past catalysts played out
Istaroxime
Cardiogenic Shock
Lucinactant
Acute Hypoxemic Respiratory Failure
Rostafuroxin
Hypertension
Lucinactant for Inhalation
Respiratory Distress Syndrome
Lucinactant delivered via investigational delivery device
Respiratory Distress Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Istaroxime | Phase 2 | Cardiogenic Shock | - | - |
Lucinactant | Phase 2 | Acute Hypoxemic Respiratory Failure | - | - |
Rostafuroxin | Phase 2 | Hypertension | - | - |
Lucinactant for Inhalation | Phase 2 | Respiratory Distress Syndrome | - | - |
Lucinactant delivered via investigational delivery device | Phase 2 | Respiratory Distress Syndrome | - | - |
Frequently asked questions
What is in Windtree Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Windtree Therapeutics, Inc.'s (WINT) pipeline across Phase 2. Its lead program is Istaroxime (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Windtree Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Windtree Therapeutics, Inc. (WINT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track WINT biotech catalysts?→
Add WINT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Windtree Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.